INNV vs. WGS, TALK, PNTG, DCGO, SHCR, PIII, USPH, PRVA, ABSI, and IGMS
Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include GeneDx (WGS), Talkspace (TALK), The Pennant Group (PNTG), DocGo (DCGO), Sharecare (SHCR), P3 Health Partners (PIII), U.S. Physical Therapy (USPH), Privia Health Group (PRVA), Absci (ABSI), and IGM Biosciences (IGMS). These companies are all part of the "medical" sector.
GeneDx (NASDAQ:WGS) and InnovAge (NASDAQ:INNV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
GeneDx has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.
GeneDx presently has a consensus target price of $18.00, suggesting a potential downside of 19.61%. InnovAge has a consensus target price of $6.50, suggesting a potential upside of 75.68%. Given GeneDx's higher possible upside, analysts plainly believe InnovAge is more favorable than GeneDx.
InnovAge has a net margin of -4.16% compared to InnovAge's net margin of -60.86%. GeneDx's return on equity of -10.51% beat InnovAge's return on equity.
GeneDx received 3 more outperform votes than InnovAge when rated by MarketBeat users. Likewise, 42.86% of users gave GeneDx an outperform vote while only 0.00% of users gave InnovAge an outperform vote.
61.7% of GeneDx shares are held by institutional investors. Comparatively, 12.3% of InnovAge shares are held by institutional investors. 28.1% of GeneDx shares are held by company insiders. Comparatively, 0.4% of InnovAge shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, GeneDx had 2 more articles in the media than InnovAge. MarketBeat recorded 6 mentions for GeneDx and 4 mentions for InnovAge. InnovAge's average media sentiment score of 1.11 beat GeneDx's score of 0.32 indicating that GeneDx is being referred to more favorably in the media.
InnovAge has higher revenue and earnings than GeneDx. InnovAge is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.
Summary
GeneDx beats InnovAge on 11 of the 18 factors compared between the two stocks.
Get InnovAge News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InnovAge Competitors List
Related Companies and Tools
